Only the top-line result is available at the moment, so the big question is whether Keytruda can do better in BTC than Imfinzi, which improved OS by 20% when added to chemo in the TOPAZ-1 trial ...

The results showed a 17% increase in OS for Keytruda (pembrolizumab), coming in at a median of 12.7 months for the combination versus 10.9 months for chemo alone. Biliary tract cancer occurs in ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

In KEYNOTE-A18, KEYTRUDA in combination with concurrent CRT demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) and PFS compared to concurrent ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda is the standard of care for patients ... it will be key to determine whether ivonescimab improves overall survival, ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

In KEYNOTE-A18, KEYTRUDA in combination with concurrent CRT demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) and PFS compared to concurrent CRT ...